Genentech’s Vabysmo Improved Retinal Vein Occlusionin Phase 3

 

• Vabysmo met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept
• More Vabysmo patients showed an absence of blood vessel leakage in the retina compared to aflibercept in a pre-specified exploratory endpoint
• If approved, RVO would be the third indication for Vabysmo in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema

https://www.biospace.com/article/releases/new-phase-iii-data-show-genentech-s-vabysmo-rapidly-improved-vision-and-reduced-retinal-fluid-in-people-with-retinal-vein-occlusion-rvo-/